Partners Pfizer (USA) and BioNTech (Germany) have announced that they will test a third dose of 3 μg (micrograms) of their mRNA vaccine. coronavirus in children under five years.
As they made known, The two doses of their vaccine, which were tested in children aged two, three and four years, failed to elicit an immune response comparable to that in adolescents and adults.. On the other, their vaccine gave rise to an immune response in children six months to two years old.
The companies assured that "No security issues detected" "The decision to evaluate a third installment in children six months to five years old reflects the commitment of companies to carefully choose the right dose to optimize the risk-benefit profile," they said.
The "blind" clinical trial will now include a third dose at least two months after the second dose, with the aim of increasing the protection of children up to five years of age. If the three doses are finally successful, the companies have announced that they will submit their test data to regulators within the first half of 2022, so that they can receive an urgent marketing authorization for their vaccine in young children.
They also announced that plan to try a third dose of 10 μg in children five to 12 years old. They also started a third dose subset of 10 or 30 μg in 600 adolescents aged 12-17 years. These tests are related to the emergence of the new Omicron variant and the initial findings that people who take a booster dose have a greater degree of protection.
via: Newsbeast